{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:35:09Z","timestamp":1757619309969,"version":"3.44.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005046","name":"Natural Science Foundation of Heilongjiang Province of China","doi-asserted-by":"crossref","award":["LH2022H004"],"award-info":[{"award-number":["LH2022H004"]}],"id":[{"id":"10.13039\/501100005046","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81774024"],"award-info":[{"award-number":["81774024"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Special Project of Traditional Chinese Medicine in Heilongjiang Province of China","award":["ZYW2023- -132"],"award-info":[{"award-number":["ZYW2023- -132"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Immunol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>To examine whether pidotimod affects the progression and severity of experimental autoimmune encephalomyelitis (EAE), a classic animal model of multiple sclerosis (MS), the balance of splenic lymphocytes in pidotimod-treated and untreated EAE mice was examined.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>C57BL\/6J mice were immunized by subcutaneous injection of an emulsion containing MOG35-55, with subsequent monitoring of their general condition and clinical scores following treatment with pidotimod or saline solution (vehicle control). Hematoxylin and eosin (H&amp;E) staining, along with flow cytometry (FCM), was employed to evaluate leukocyte infiltration, while FluoroMyelin\u2122 Green staining was utilized to assess axonal demyelination in the central nervous system (CNS). Additionally, FCM was conducted to investigate the effects of pidotimod on splenic lymphocytes both in vitro and in vivo during the peak stage of EAE.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Compared to the vehicle control, pidotimod treatment significantly reduced the clinical scores, decreased leukocyte infiltration in the spinal cord and brain, and suppressed demyelination in the spinal cord. Furthermore, pidotimod treatment markedly increased the populations of CD4<jats:sup>+<\/jats:sup> CD25<jats:sup>+<\/jats:sup> Foxp3<jats:sup>+<\/jats:sup> regulatory T cells (Tregs) and CD8<jats:sup>+<\/jats:sup> Foxp3<jats:sup>+<\/jats:sup> Tregs, while decreasing the numbers of CD4<jats:sup>+<\/jats:sup> IFN-\u03b3<jats:sup>+<\/jats:sup> helper T cells (Th1), CD4<jats:sup>+<\/jats:sup> IL-17<jats:sup>+<\/jats:sup> helper T cells (Th17), and CD8<jats:sup>+<\/jats:sup> IL-17<jats:sup>+<\/jats:sup> cytotoxic T cells (Tc17) in the spleen during the peak stage of EAE both in vitro and in vivo. Additionally, pidotimod treatment significantly diminished the population of B220<jats:sup>+<\/jats:sup> TNF-\u03b1<jats:sup>+<\/jats:sup> B cells in the spleen at the peak stage of EAE both in vitro and in vivo.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The present study preliminarily explored the effects and potential immunomodulator mechanisms of pidotimod in treating EAE mice. Results indicated that pidotimod treatment decreased the percentages of CD4<jats:sup>+<\/jats:sup> IFN-\u03b3<jats:sup>+<\/jats:sup> Th1 cells, CD4<jats:sup>+<\/jats:sup> IL-17<jats:sup>+<\/jats:sup> Th17 cells, CD8<jats:sup>+<\/jats:sup> IL-17<jats:sup>+<\/jats:sup> Tc17 cells and B220<jats:sup>+<\/jats:sup> TNF-\u03b1<jats:sup>+<\/jats:sup> B cells, while increasing the percentages of CD4<jats:sup>+<\/jats:sup> CD25<jats:sup>+<\/jats:sup> Foxp3<jats:sup>+<\/jats:sup> Tregs and CD8<jats:sup>+<\/jats:sup> Foxp3<jats:sup>+<\/jats:sup> Tregs in the spleen at the peak stage of EAE. Additionally, pidotimod reduced leukocyte infiltration into the spinal cord and brain, as well as demyelination in the spinal cord. These findings suggest that the neuroprotective effects of pidotimod in EAE mice may be its ability to regulate the balance of splenic lymphocytes.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12865-025-00736-1","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T16:37:11Z","timestamp":1753115831000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pidotimod alleviated experimental autoimmune encephalomyelitis by regulating the balance of splenic lymphocytes"],"prefix":"10.1186","volume":"26","author":[{"given":"Yanping","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sifan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoru","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junfeng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhixin","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiujuan","family":"Lang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xijun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hulun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,21]]},"reference":[{"issue":"20","key":"736_CR1","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1001\/jama.2022.14236","volume":"328","author":"R Marcus","year":"2022","unstructured":"Marcus R. What Is Multiple Sclerosis? JAMA. 2022;328(20):2078.","journal-title":"JAMA"},{"issue":"6","key":"736_CR2","doi-asserted-by":"publisher","first-page":"ITC81","DOI":"10.7326\/AITC202106150","volume":"174","author":"MJ Olek","year":"2021","unstructured":"Olek MJ. Multiple Sclerosis. Ann Intern Med. 2021;174(6):ITC81-ITCI96.","journal-title":"Ann Intern Med"},{"issue":"10130","key":"736_CR3","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","volume":"391","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. Lancet. 2018;391(10130):1622\u201336.","journal-title":"Lancet"},{"issue":"4","key":"736_CR4","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.neuron.2018.01.021","volume":"97","author":"C Baecher-Allan","year":"2018","unstructured":"Baecher-Allan C, Kaskow BJ, Weiner HL. Multiple Sclerosis: Mechanisms and Immunotherapy. Neuron. 2018;97(4):742\u201368.","journal-title":"Neuron"},{"key":"736_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jaut.2013.06.008","volume":"45","author":"M Rangachari","year":"2013","unstructured":"Rangachari M, Kuchroo VK. Using EAE to better understand principles of immune function and autoimmune pathology. J Autoimmun. 2013;45:31\u20139.","journal-title":"J Autoimmun"},{"issue":"8","key":"736_CR6","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.it.2013.04.006","volume":"34","author":"SB Simmons","year":"2013","unstructured":"Simmons SB, Pierson ER, Lee SY, Goverman JM. Modeling the heterogeneity of multiple sclerosis in animals. Trends Immunol. 2013;34(8):410\u201322.","journal-title":"Trends Immunol"},{"issue":"3","key":"736_CR7","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.7150\/thno.87130","volume":"14","author":"Y Wei","year":"2024","unstructured":"Wei Y, Li W, Huang J, Braunstein Z, Liu X, Li X, Deiuliis J, Chen J, Min X, Yang H, et al. Midline-1 regulates effector T cell motility in experimental autoimmune encephalomyelitis via mTOR\/microtubule pathway. Theranostics. 2024;14(3):1168\u201380.","journal-title":"Theranostics"},{"issue":"7","key":"736_CR8","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41582-021-00498-5","volume":"17","author":"MT Cencioni","year":"2021","unstructured":"Cencioni MT, Mattoscio M, Magliozzi R, Bar-Or A, Muraro PA. B cells in multiple sclerosis - from targeted depletion to immune reconstitution therapies. Nat Rev Neurol. 2021;17(7):399\u2013414.","journal-title":"Nat Rev Neurol"},{"issue":"6","key":"736_CR9","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/S1474-4422(21)00063-6","volume":"20","author":"A Bar-Or","year":"2021","unstructured":"Bar-Or A, Li R. Cellular immunology of relapsing multiple sclerosis: interactions, checks, and balances. Lancet Neurol. 2021;20(6):470\u201383.","journal-title":"Lancet Neurol"},{"issue":"11","key":"736_CR10","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/S1474-4422(21)00325-2","volume":"20","author":"R Hohlfeld","year":"2021","unstructured":"Hohlfeld R. Multiple sclerosis meets systems immunology. Lancet Neurol. 2021;20(11):887\u20138.","journal-title":"Lancet Neurol"},{"issue":"6","key":"736_CR11","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1038\/s41423-020-00618-z","volume":"18","author":"MJ Mansilla","year":"2021","unstructured":"Mansilla MJ, Presas-Rodriguez S, Teniente-Serra A, Gonzalez-Larreategui I, Quirant-Sanchez B, Fondelli F, Djedovic N, Iwaszkiewicz-Grzes D, Chwojnicki K, Miljkovic D, et al. Paving the way towards an effective treatment for multiple sclerosis: advances in cell therapy. Cell Mol Immunol. 2021;18(6):1353\u201374.","journal-title":"Cell Mol Immunol"},{"issue":"4","key":"736_CR12","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.cmet.2020.07.001","volume":"32","author":"T Alissafi","year":"2020","unstructured":"Alissafi T, Kalafati L, Lazari M, Filia A, Kloukina I, Manifava M, Lim J-H, Alexaki VI, Ktistakis NT, Doskas T, et al. Mitochondrial Oxidative Damage Underlies Regulatory T Cell Defects in Autoimmunity. Cell Metabolism. 2020;32(4):591-604. e7.","journal-title":"Cell Metabolism"},{"issue":"21","key":"736_CR13","doi-asserted-by":"publisher","first-page":"e162788","DOI":"10.1172\/JCI162788","volume":"133","author":"BD Clarkson","year":"2023","unstructured":"Clarkson BD, Grund EM, Standiford MM, Mirchia K, Westphal MS, Muschler LS, Howe CL. CD8 + T cells recognizing a neuron-restricted antigen injure axons in a model of multiple sclerosis. J Clin Invest. 2023;133(21):e162788.","journal-title":"J Clin Invest"},{"issue":"3","key":"736_CR14","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41573-020-00092-2","volume":"20","author":"DSW Lee","year":"2021","unstructured":"Lee DSW, Rojas OL, Gommerman JL. B cell depletion therapies in autoimmune disease: advances and mechanistic insights. Nat Rev Drug Discov. 2021;20(3):179\u201399.","journal-title":"Nat Rev Drug Discov"},{"key":"736_CR15","doi-asserted-by":"publisher","first-page":"760","DOI":"10.3389\/fimmu.2020.00760","volume":"11","author":"J van Langelaar","year":"2020","unstructured":"van Langelaar J, Rijvers L, Smolders J, van Luijn MM. B and T Cells Driving Multiple Sclerosis: Identity\u00a0Mechanisms and Potential Triggers. Front Immunol. 2020;11:760.","journal-title":"Front Immunol"},{"issue":"5","key":"736_CR16","doi-asserted-by":"publisher","first-page":"422","DOI":"10.4103\/lungindia.lungindia_39_19","volume":"36","author":"A Mahashur","year":"2019","unstructured":"Mahashur A, Thomas PK, Mehta P, Nivangune K, Muchhala S, Jain R. Pidotimod: In-depth review of current evidence. Lung India: Official Organ of Indian Chest Soc. 2019;36(5):422\u201333.","journal-title":"Lung India: Official Organ of Indian Chest Soc"},{"key":"736_CR17","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.pupt.2017.03.005","volume":"44","author":"D Trabattoni","year":"2017","unstructured":"Trabattoni D, Clerici M, Centanni S, Mantero M, Garziano M, Blasi F. Immunomodulatory effects of pidotimod in adults with community-acquired pneumonia undergoing standard antibiotic therapy. Pulm Pharmacol Ther. 2017;44:24\u20139.","journal-title":"Pulm Pharmacol Ther"},{"issue":"7","key":"736_CR18","first-page":"563","volume":"20","author":"H-T Lyu","year":"2018","unstructured":"Lyu H-T, Shen T-T, Zheng J-S, Xu H-Q. Clinical effect of pidotimod oral liquid as adjuvant therapy for infectious mononucleosis. Zhongguo Dang Dai Er Ke Za Zhi. 2018;20(7):563\u20136.","journal-title":"Zhongguo Dang Dai Er Ke Za Zhi"},{"issue":"4","key":"736_CR19","doi-asserted-by":"publisher","first-page":"4151","DOI":"10.3892\/mmr.2017.7046","volume":"16","author":"L-Q Fu","year":"2017","unstructured":"Fu L-Q, Li Y-L, Fu A-K, Wu Y-P, Wang Y-Y, Hu S-L, Li W-F. Pidotimod exacerbates allergic pulmonary infection in an OVA mouse model of asthma. Mol Med Rep. 2017;16(4):4151\u20138.","journal-title":"Mol Med Rep"},{"issue":"1","key":"736_CR20","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1172\/JCI132531","volume":"130","author":"CA Wagner","year":"2020","unstructured":"Wagner CA, Roqu\u00e9 PJ, Mileur TR, Liggitt D, Goverman JM. Myelin-specific CD8 + T cells exacerbate brain inflammation in CNS autoimmunity. J Clin Invest. 2020;130(1):203\u201313.","journal-title":"J Clin Invest"},{"issue":"7631","key":"736_CR21","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1038\/540S1a","volume":"540","author":"B Owens","year":"2016","unstructured":"Owens B. Multiple sclerosis. Nature. 2016;540(7631):S1.","journal-title":"Nature"},{"issue":"7359","key":"736_CR22","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nature10251","volume":"476","author":"S Sawcer","year":"2011","unstructured":"Sawcer S, Hellenthal G, Pirinen M, Spencer CCA, Patsopoulos NA, Moutsianas L, Dilthey A, Su Z, Freeman C, Hunt SE, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011;476(7359):214\u20139.","journal-title":"Nature"},{"key":"736_CR23","doi-asserted-by":"publisher","first-page":"822919","DOI":"10.3389\/fimmu.2022.822919","volume":"13","author":"S Krishnarajah","year":"2022","unstructured":"Krishnarajah S, Becher B. TH Cells and Cytokines in Encephalitogenic Disorders. Front Immunol. 2022;13:822919.","journal-title":"Front Immunol"},{"issue":"4","key":"736_CR24","doi-asserted-by":"publisher","first-page":"a029025","DOI":"10.1101\/cshperspect.a029025","volume":"8","author":"BJ Kaskow","year":"2018","unstructured":"Kaskow BJ, Baecher-Allan C. Effector T Cells in Multiple Sclerosis. Cold Spring Harb Perspect Med. 2018;8(4):a029025.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"736_CR25","doi-asserted-by":"publisher","first-page":"103240","DOI":"10.1016\/j.redox.2024.103240","volume":"75","author":"M Wu","year":"2024","unstructured":"Wu M, Yu S, Yan S, Wu M, Zhang L, Chen S, Shi D, Liu S, Fan Y, Lin X, et al. Peroxynitrite reduces Treg cell expansion and function by mediating IL-2R nitration and aggravates multiple sclerosis pathogenesis. Redox Biology. 2024;75:103240.","journal-title":"Redox Biology"},{"issue":"Pt 8","key":"736_CR26","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1093\/brain\/awh578","volume":"128","author":"MA Friese","year":"2005","unstructured":"Friese MA, Fugger L. Autoreactive CD8 + T cells in multiple sclerosis: a new target for therapy? Brain. 2005;128(Pt 8):1747\u201363.","journal-title":"Brain"},{"key":"736_CR27","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.3389\/fimmu.2018.02336","volume":"9","author":"AW Boyden","year":"2018","unstructured":"Boyden AW, Brate AA, Karandikar NJ. Early IFN\u03b3-Mediated and Late Perforin-Mediated Suppression of Pathogenic CD4 T Cell Responses Are Both Required for Inhibition of Demyelinating Disease by CNS-Specific Autoregulatory CD8 T Cells. Front Immunol. 2018;9:2336.","journal-title":"Front Immunol"},{"issue":"1","key":"736_CR28","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1172\/JCI63681","volume":"123","author":"M Huber","year":"2013","unstructured":"Huber M, Heink S, Pagenstecher A, Reinhard K, Ritter J, Visekruna A, Guralnik A, Bollig N, Jeltsch K, Heinemann C, et al. IL-17A secretion by CD8 + T cells supports Th17-mediated autoimmune encephalomyelitis. J Clin Invest. 2013;123(1):247\u201360.","journal-title":"J Clin Invest"},{"issue":"737","key":"736_CR29","doi-asserted-by":"publisher","first-page":"eadi0295","DOI":"10.1126\/scitranslmed.adi0295","volume":"16","author":"AA Wang","year":"2024","unstructured":"Wang AA, Luessi F, Neziraj T, P\u00f6ssnecker E, Zuo M, Engel S, Hanuscheck N, Florescu A, Bugbee E, Ma XI, et al. B cell depletion with anti-CD20 promotes neuroprotection in a BAFF-dependent manner in mice and humans. Sci Transl Med. 2024;16(737):eadi0295.","journal-title":"Sci Transl Med"},{"key":"736_CR30","doi-asserted-by":"publisher","first-page":"102053","DOI":"10.1016\/j.redox.2021.102053","volume":"45","author":"J Kim","year":"2021","unstructured":"Kim J, Islam SMT, Qiao F, Singh AK, Khan M, Won J, Singh I. Regulation of B cell functions by S-nitrosoglutathione in the EAE model. Redox Biology. 2021;45:102053.","journal-title":"Redox Biology"},{"issue":"310","key":"736_CR31","doi-asserted-by":"publisher","first-page":"310ra166","DOI":"10.1126\/scitranslmed.aab4176","volume":"7","author":"R Li","year":"2015","unstructured":"Li R, Rezk A, Miyazaki Y, Hilgenberg E, Touil H, Shen P, Moore CS, Michel L, Althekair F, Rajasekharan S, et al. Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy. Sci Transl Med. 2015;7(310):310ra166.","journal-title":"Sci Transl Med"},{"key":"736_CR32","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.phrs.2015.04.007","volume":"97","author":"C Mameli","year":"2015","unstructured":"Mameli C, Pasinato A, Picca M, Bedogni G, Pisanelli S, Zuccotti GV. Pidotimod for the prevention of acute respiratory infections in healthy children entering into daycare: A double blind randomized placebo-controlled study. Pharmacological Research. 2015;97:79\u201383.","journal-title":"Pharmacological Research"},{"key":"736_CR33","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.intimp.2018.11.043","volume":"67","author":"H Niu","year":"2019","unstructured":"Niu H, Wang R, Jia Y-T, Cai Y. Pidotimod, an immunostimulant in pediatric recurrent respiratory tract infections: A meta-analysis of randomized controlled trials. Int Immunopharmacol. 2019;67:35\u201345.","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"736_CR34","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1007\/s00726-014-1676-4","volume":"46","author":"S Hu","year":"2014","unstructured":"Hu S, Fu X, Fu A, Du W, Ji J, Li W. The regulatory peptide pidotimod facilitates M2 macrophage polarization and its function. Amino Acids. 2014;46(5):1177\u201385.","journal-title":"Amino Acids"},{"issue":"24","key":"736_CR35","doi-asserted-by":"publisher","first-page":"5765","DOI":"10.3390\/jcm10245765","volume":"10","author":"P Santus","year":"2021","unstructured":"Santus P, Radovanovic D, Garziano M, Pini S, Croce G, Fuccia G, Spitaleri D, Biasin M, Clerici M, Trabattoni D. Anti-Inflammatory Effects of Immunostimulation in Patients with COVID-19 Pneumonia. J Clin Med. 2021;10(24):5765.","journal-title":"J Clin Med"},{"issue":"3","key":"736_CR36","doi-asserted-by":"publisher","first-page":"260","DOI":"10.2174\/1570162X18666210111102046","volume":"19","author":"C Ucciferri","year":"2021","unstructured":"Ucciferri C, Falasca K, Reale M, Tamburro M, Auricchio A, Vignale F, Vecchiet J. Pidotimod and Immunological Activation in Individuals Infected with HIV. Curr HIV Res. 2021;19(3):260\u20138.","journal-title":"Curr HIV Res"},{"issue":"12","key":"736_CR37","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/j.intimp.2009.08.010","volume":"9","author":"C Giagulli","year":"2009","unstructured":"Giagulli C, Noerder M, Avolio M, Becker PD, Fiorentini S, Guzman CA, Caruso A. Pidotimod promotes functional maturation of dendritic cells and displays adjuvant properties at the nasal mucosa level. Int Immunopharmacol. 2009;9(12):1366\u201373.","journal-title":"Int Immunopharmacol"},{"key":"736_CR38","doi-asserted-by":"publisher","first-page":"1017484","DOI":"10.3389\/fnmol.2022.1017484","volume":"15","author":"N Saez-Calveras","year":"2022","unstructured":"Saez-Calveras N, Brewster AL, Stuve O. The validity of animal models to explore the pathogenic role of the complement system in multiple sclerosis: A review. Front Mol Neurosci. 2022;15:1017484.","journal-title":"Front Mol Neurosci"}],"container-title":["BMC Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-025-00736-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12865-025-00736-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-025-00736-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T16:22:01Z","timestamp":1757262121000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcimmunol.biomedcentral.com\/articles\/10.1186\/s12865-025-00736-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,21]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["736"],"URL":"https:\/\/doi.org\/10.1186\/s12865-025-00736-1","relation":{},"ISSN":["1471-2172"],"issn-type":[{"type":"electronic","value":"1471-2172"}],"subject":[],"published":{"date-parts":[[2025,7,21]]},"assertion":[{"value":"22 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The experiments were conducted in compliance with the Care and Use of Laboratory Animal Guidelines established by the China National Institute of Health (HMUIRB20120005) and were approved by the Institutional Review Board of Harbin Medical University. All efforts were made to minimize suffering.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"53"}}